Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.37)
# 4,289
Out of 5,154 analysts
17
Total ratings
26.67%
Success rate
-23.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $7.95 | +843.40% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.63 | +881.60% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.10 | +8,697.65% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.79 | +111.08% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $28.76 | +247.71% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.41 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.83 | +204,818.03% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.86 | +1,643.98% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.82 | +992.23% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.80 | +650.00% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $57.47 | +56.60% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.47 | +12,450.61% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.25 | +2,687,900.00% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $7.95
Upside: +843.40%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.63
Upside: +881.60%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.10
Upside: +8,697.65%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.79
Upside: +111.08%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $28.76
Upside: +247.71%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.41
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.83
Upside: +204,818.03%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.86
Upside: +1,643.98%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.82
Upside: +992.23%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.80
Upside: +650.00%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $57.47
Upside: +56.60%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.47
Upside: +12,450.61%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.25
Upside: +2,687,900.00%